首頁 > 市場調查報告書 > 製藥

消化器

非酒精性脂肪性肝炎生物標記市場規模、佔有率和成長分析（按類型、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1897814

非酒精性脂肪性肝炎生物標記市場規模、佔有率和成長分析（按類型、最終用戶和地區分類）—2026-2033年產業預測

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share, and Growth Analysis, By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers), By End User (Research Institutes and Academics, Diagnostic Centres), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球非酒精性脂肪性肝炎生物標記市場規模預計在 2024 年達到 13 億美元，從 2025 年的 16.7 億美元成長到 2033 年的 125.9 億美元，在預測期（2026-2033 年）內複合年成長率為 28.7%。

全球非酒精性脂肪性肝炎（NASH）生物標記市場正經歷強勁成長，這主要受NASH盛行率上升的推動。 NASH與肥胖和代謝紊亂密切相關。疾病發生率的上升推動了對精準生物標記的需求，這些標記對於早期診斷、監測疾病進展和評估治療效果至關重要。生物標記對於識別高風險族群、區分NASH與其他肝臟疾病以及評估疾病嚴重程度至關重要。研發領域的進步，特別是新型生物標記的發現和非侵入性診斷工具的開發，也推動了市場的發展。這個快速成長的市場能夠很好地滿足對有效診斷和監測解決方案的迫切需求，並為基於生物標記的創新干預方法提供了巨大的機會。

全球非酒精性脂肪性肝炎生物標記市場促進因素

全球非酒精性脂肪性肝炎 (NASH) 生物標記市場的主要促進因素是這種肝臟疾病在全球範圍內的日益普及。 NASH 會導致肝臟脂肪堆積，進而引發發炎和損傷。肥胖率上升、久坐不動的生活方式和不健康的飲食習慣等因素都加劇了 NASH 的發病率。因此，人們越來越需要可靠的生物標記來有效診斷疾病、監測其進展並評估治療效果。隨著人們對該疾病的認知不斷提高，以及認知到改進診斷解決方案至關重要，對 NASH 生物標記的需求持續激增。

影響全球非酒精性脂肪性肝炎生物標記市場的因素

全球非酒精性脂肪性肝炎 (NASH) 生物標記市場面臨的主要挑戰之一是缺乏標準化的生物標記和監管障礙。用於診斷和監測 NASH 的生物標記的開發和檢驗是一個複雜的過程，這使得它們的廣泛應用難以實現。生物標記選擇和應用方面缺乏共識進一步加劇了這個問題，阻礙了它們在臨床實踐中的廣泛應用。此外，監管機構嚴格的檢驗要求對企業而言既耗時又昂貴。透過進一步的研究、標準化和完善監管指導來應對這些挑戰，對於充分發揮 NASH 生物標記在改善患者預後方面的潛力至關重要。

全球非酒精性脂肪性肝炎生物標記市場趨勢

全球非酒精性脂肪性肝炎 (NASH) 生物標記市場的一個顯著趨勢是，人們越來越關注非侵入性診斷方法。鑑於 NASH 的複雜性和進行性性，及時準確的診斷對於有效的疾病管理和治療至關重要。非侵入性生物標記，包括血液檢測和先進的影像學技術，因其優於傳統侵入性肝臟切片檢查的優勢而日益普及，這些優勢包括減輕患者負擔、節省成本和普及性。這種向可靠且便利的診斷工具的轉變不僅有望改善患者預後，還能提高臨床試驗的效率，從而推動 NASH 生物標記市場的成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Genfit SA（France）
Gilead Sciences, Inc.（United States）
Novartis AG（Switzerland）
Pfizer Inc.（United States）
Siemens Healthineers AG（Germany）
Bio-Rad Laboratories, Inc.（United States）
Abbott Laboratories（United States）
Prometheus Laboratories Inc.（United States）
NGM Biopharmaceuticals, Inc.（United States）
Metabolon, Inc.（United States）
Perspectum Ltd（United Kingdom）
Precision Medicine Group, Inc.（United States）
Grifols, SA（Spain）
Hologic, Inc.（United States）
Quest Diagnostics Incorporated（United States）
F. Hoffmann-La Roche Ltd（Switzerland）
Biopredictive（France）

結論與建議

簡介目錄

Product Code: SQMIG35A2593

Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.67 Billion in 2025 to USD 12.59 Billion by 2033, growing at a CAGR of 28.7% during the forecast period (2026-2033).

The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing robust growth, driven by the rising prevalence of NASH linked to obesity and metabolic disorders. As the disease incidence escalates, there is an increasing demand for precise biomarkers essential for early diagnosis, monitoring disease progression, and evaluating therapeutic responses. Biomarkers are vital for identifying individuals at risk, distinguishing NASH from other liver diseases, and assessing severity levels. The market is also benefiting from advancements in research and development, particularly the identification of novel biomarkers and the creation of non-invasive diagnostic tools. This burgeoning market is well-positioned to meet the critical need for effective diagnostic and monitoring solutions, presenting substantial opportunities for innovative biomarker-based interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-alcoholic Steatohepatitis Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-alcoholic Steatohepatitis Biomarkers Market Segments Analysis

Global Non-alcoholic SteatohepatitisbiomarkersMarket is segmented by Type, End User and region. Based on Type, the market is segmented into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Based on End User, the market is segmented into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-alcoholic Steatohepatitis Biomarkers Market

A significant driver of the global Non-alcoholic Steatohepatitis (NASH) biomarkers market is the increasing global prevalence of this liver condition, characterized by fat accumulation in the liver leading to inflammation and damage. Factors such as rising obesity rates, sedentary lifestyles, and poor dietary choices are contributing to the heightened occurrence of NASH. Consequently, there is a growing necessity for reliable biomarkers that can effectively diagnose the disease, monitor its progression, and evaluate treatment responses. The demand for NASH biomarkers continues to surge, fueled by heightened awareness of the condition and the imperative for enhanced diagnostic solutions.

Restraints in the Global Non-alcoholic Steatohepatitis Biomarkers Market

One of the major challenges facing the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is the absence of standardized biomarkers alongside regulatory hurdles. The intricate processes involved in the development and validation of these biomarkers for diagnosing and monitoring NASH contribute to the difficulty in achieving broad acceptance. A lack of agreement on the selection and application of biomarkers further complicates matters, making it hard for them to gain traction in clinical settings. Moreover, the stringent validation requirements set by regulatory bodies can be both time-consuming and expensive for companies. Addressing these issues through further research, standardization, and improved regulatory guidance is essential for realizing the full potential of NASH biomarkers in enhancing patient outcomes.

Market Trends of the Global Non-alcoholic Steatohepatitis Biomarkers Market

A prominent trend in the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is the escalating emphasis on non-invasive diagnostic methodologies. Given the intricate nature and progressive characteristics of NASH, timely and precise diagnosis is essential for effective disease management and treatment. Non-invasive biomarkers, including blood-based tests and advanced imaging techniques, are gaining popularity due to their advantages over traditional invasive liver biopsies, such as minimizing patient discomfort, lowering costs, and facilitating broader accessibility. This shift towards reliable and convenient diagnostic tools not only promises to improve patient outcomes but also enhances the efficiency of clinical trials, propelling the growth of the NASH biomarkers market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by Type & CAGR (2026-2033)

Market Overview
Hepatic Fibrosis Biomarkers
Serum Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by End User & CAGR (2026-2033)

Market Overview
Research Institutes and Academics
Diagnostic Centres
Pharmaceutical Companies and CROs
Hospitals and Clinics
Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size & CAGR (2026-2033)

North America (Type, End User)
- US
- Canada
Europe (Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Genfit SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Prometheus Laboratories Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NGM Biopharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metabolon, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perspectum Ltd (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Precision Medicine Group, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biopredictive (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments